louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT07023640: Application of the CD73-Targeted Probe ⁶⁸Ga-DOTA-mPNE PET/CT Imaging in the Diagnosis of Malignant Tumors
Official title: Application of the CD73-Targeted Probe ⁶⁸Ga-DOTA-mPNE PET/CT Imaging in the Diagnosis of Malignant Tumors
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Malignant Neoplasms of Brain
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2025-06-17
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study aims to perform ⁶⁸Ga-DOTA-mPNE PET/CT imaging in patients with clinically suspected or confirmed malignant tumors, in order to evaluate tracer uptake in lesions and analyze CD73 expression levels. In a subgroup of up to 10 participants, dynamic PET/CT imaging will be conducted for up to 90 minutes post-injection to assess the tracer's biodistribution and pharmacokinetic properties.Correlation analyses with relevant clinical indicators (such as pathology, immunohistochemistry, and molecular markers) will be carried out to further assess the diagnostic performance and clinical value of ⁶⁸Ga-DOTA-mPNE PET/CT in guiding tumor diagnosis and treatment. This study is expected to provide a novel molecular imaging tool for malignancies and offer clear, intuitive PET/CT-based evidence to support clinical diagnosis, differential diagnosis, and therapeutic decision-making.


Eligibility criteria: Inclusion Criteria:

1. Age ≥18 years, with an expected survival of ≥12 weeks.
2. No prior radiotherapy or chemotherapy; eligible for surgery or biopsy to obtain pathological diagnosis.
3. At least one measurable target lesion according to RECIST version 1.1 (Response Evaluation Criteria in Solid Tumors).
4. Written informed consent obtained and able to comply with follow-up requirements.

Exclusion Criteria:

1. Severe hepatic or renal dysfunction.
2. Women who are planning to conceive, currently pregnant, breastfeeding, or intend to have children during the study period are not eligible. Fertile participants must use effective contraception during the study.
3. Unable to lie flat for 30 minutes.
4. Refusal to participate in this clinical study.
5. Claustrophobia or other psychiatric disorders.
6. Any other condition deemed unsuitable for study participation by the investigator.

Primary outcomes:
measure: SUVmax
timeFrame: Time Frame: Day 1 (on the day of PET/CT imaging)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00075140: Family Health After Predictive Huntington Disease (HD) Testing
Official title: Family Health After Predictive Huntington Disease Testing
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Huntington Disease
Keywords: Patient Care Management
Family
Huntington's Disease
Lead sponsor: National Institute of Nursing Research (NINR)
Sponsor class: NIH
First posted: 2004-01-05
Enrollment: 422
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Sampling method: PROBABILITY_SAMPLE
Study population: Family members or significant others, age 14 or older, of persons who 1) have received a positive result from predictive testing for a mutation in the HD gene, 2) are symptomatic and living at home, and 3) are symptomatic and are living in a long-term care institution were the population of interest for this study.

Brief summary: The purpose of this study is to identify health management concerns and needs of family members of asymptomatic and symptomatic persons with mutation in the gene for Huntington Disease (HD).

Detailed description: This is an observational study with three phases. In Phase 1, focus groups consisting of family members of persons with HD Gene mutation will be conducted and data collected to be analyzed through content analysis to identify salient themes and key issues. In Phase 2, a survey instrument will be developed and field-tested in order to describe the health care needs, management strategies, and needs for health and social services of relative/significant others of asymptomatic and symptomatic persons with the mutation in the gene for HD.

In Phase 3, the survey will be distributed to family members of asymptomatic and symptomatic persons with mutation in the gene for HD and frequencies and comparisons of survey responses according to respondent characteristics will be reported.

Eligibility criteria: * Family members of asymptomatic and symptomatic persons with mutation in the gene for Huntington Disease

Primary outcomes:
measure: Impact of a positive HD test or presence of HD on a family members perceptions of: health problems, emotional and functional health status, resources/strategies for managing problems, helpfulness, and services needed to help family members cope.
timeFrame: Over 6 yr span
Secondary outcomes:
measure: Describe the health care needs, management strategies, and needs for health and social services of a broader sample of relatives/significant others in families in which a person has a gene mutation for HD.
timeFrame: Over 6 yr span
Other outcomes:
Locations:
city: Iowa City
country: United States
facility: The University of Iowa College of Nursing
state: Iowa
Study officials:
affiliation: University of Iowa
name: Janet K Williams, PhD, RN, FAAN
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06815640: Effects of Intermittent Pneumatic Compression on Recovery of Cyclists
Official title: Effects of Intermittent Pneumatic Compression on the Recovery of High-level Cyclists
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Recovery
Keywords: sports
compression
recovery
cycling
Lead sponsor: University of Maia
Sponsor class: OTHER
First posted: 2025-02-07
Enrollment: 24
Sex: MALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study aims to assess the recovery kinetics of road cyclists following a fatigue protocol (30 time trial).


Eligibility criteria: Inclusion Criteria:

* Road cyclists competing nationally

Exclusion Criteria:

* Injured athletes

Primary outcomes:
measure: Muscle soreness
timeFrame: Baseline, post 30 minutes, post 24 hours, and post 48 hours
measure: Creatine Kinase
timeFrame: Baseline, post 30 minutes, post 24 hours, and post 48 hours
Secondary outcomes:
measure: Low frequency fatigue - Myocece Powerdex score
timeFrame: Baseline, post 30 minutes, post 24 hours, and post 48 hours
measure: 4 min time trial
timeFrame: 24 hours post intervention
measure: Isometric knee extension srength
timeFrame: Baseline, post 30 minutes, post 24 hours, and post 48 hours
measure: Percieved fatigue
timeFrame: Baseline, post 30 minutes, post 24 hours, and post 48 hours
measure: Sleep questionnaires (consensus sleep diary)
timeFrame: Baseline, post 30 minutes, post 24 hours, and post 48 hours
measure: Perceived recovery
timeFrame: Baseline, post 30 minutes, post 24 hours, and post 48 hours
measure: Nutritional diaries
timeFrame: Baseline, post 24 hours, and post 48 hours
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02636140: Color and Pupil Function
Official title: Effect of Light Spectrum on Pupil Function
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pupil
Lead sponsor: VA Palo Alto Health Care System
Sponsor class: FED
First posted: 2015-12-21
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: This study will examine the effects of different colors of light on pupil function and alertness.


Eligibility criteria: Inclusion Criteria:

* Aged 18-35
* Good health

Exclusion Criteria:

* Sleep disorder
* Extreme chronotype
* Smoker
* Abnormal color vision
* Ocular pathology (other than mild or moderate refractive error)
* Visual field defects
* Alcohol abuse
* Use of illegal drugs

Primary outcomes:
measure: Change in pupil size
timeFrame: Baseline and 10 minutes
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03386240: Antibacterial-coated Sutures at Time of Cesarean
Official title: Antibacterial-coated Sutures at Time of Cesarean
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Surgical Site Infection
Surgical Wound Infection
Cesarean Section; Infection
Cesarean Section Complications
Lead sponsor: The University of Texas Medical Branch, Galveston
Sponsor class: OTHER
First posted: 2017-12-29
Enrollment: 1122
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Double-blinded controlled clinical trial
Primary purpose: TREATMENT

Brief summary: Abdominal closure with antibacterial-coated sutures has been shown to reduce wound infections after a number of surgical procedures, but none of the previous trials included cesarean delivery. Our objective is to determine whether use of antibacterial-coated sutures reduces surgical site infection (SSI) after cesarean delivery.

Detailed description: A review of 18 studies demonstrated a significant benefit of antimicrobial coated sutures in reducing SSI (RCTs: OR 0.72; 95% CI 0.59-0.88; observational studies: OR 0.58; 95% CI 0.40-0.83). As there are no clinical trials focusing on cesarean delivery, and because the risk factors and pathogenesis for post-cesarean SSI may not mirror other procedures, further data is needed before generalizing the WHO recommendations to cesarean procedures.

Eligibility criteria: Inclusion Criteria:

* 18-50 years of age.
* Women ≥ 24 weeks' viable gestation.
* To undergo cesarean delivery.

Exclusion Criteria:

* Patient unwilling or unable to provide consent.
* No prenatal care or a non-resident patient who is unlikely to be followed-up after delivery.
* Immunosuppressed patients: i.e., taking systemic immunosuppressant or steroids (e.g. transplant patients; not including steroids for lung maturity), HIV with CD4\<200, or other.
* Decision to use other than suture closure (e.g. secondary wound closure, mesh closure).
* Skin infection.
* Coagulopathy.
* High likelihood of additional surgical procedure beyond cesarean (e.g. scheduled hysterectomy, bowel or adnexal surgery).
* Allergy to Triclosan.
* Incarcerated individuals.

Primary outcomes:
measure: Composite of endometritis and/or wound infection and/or other post-cesarean infections
timeFrame: occurring within 30 days of delivery
Secondary outcomes:
Other outcomes:
Locations:
city: Galveston
country: United States
facility: University of Texas Medical Branch in Galveston
state: Texas
Study officials:
affiliation: University of Texas Medical Branch in Galveston
name: Benjamin Bush, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00900601: Surgical Treatment of Pelvic Joint Instability in Patients With Severe Pelvic Girdle Pain After Pregnancy and Trauma
Official title: Surgical Treatment of Pelvic Joint Instability in Patients With Severe Pelvic Girdle Pain After Pregnancy and Trauma - A Study to Measure Effect of Surgery, Analysis of Clinical Tests and Detection of Sacroiliac Instability Using RSA.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pelvic Joint Instability
Pelvic Pain
Keywords: Sacroiliac pain
Sacroiliac instability
Pelvic girdle pain
Sacroiliac arthrodesis
Arthrodesis
Surgery
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
Collaborators: name: Stiftelsen Helse og Rehabilitering
First posted: 2009-05-13
Enrollment: 9
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Pelvic girdle pain (PGP) related to pregnancy is a common reason to sick leave during pregnancy. Low back pain and PGP affects about 50% of women during pregnancy. Most of the women recover, however about 10% of the women still have complaints after birth. Most patients have positive effect from conservative treatment, but unfortunately some do still have much pain despite intensive conservative rehabilitation. Surgery has been tried on these women with various results. Surgical treatment is controversial and there is a lack of documentation. The investigators will operate 20 patients with arthrodesis to the sacroiliac joint and symphysis. Radiostereometric analysis (RSA) will be used to evaluate the joint movement in different part of the process.

Hypothesis: Severe pelvic girdle pain is caused by pelvic joint instability in some cases and surgically fixation of the affected joints can help these women to get back to a normal life.


Eligibility criteria: Inclusion Criteria:

* Pain in one or more pelvic joints.
* Minimum 2 positive clinical tests.
* High pain and disability score
* Tried adequate physiotherapy without effect.

Exclusion Criteria:

* Known psychiatric diagnosis
* Other spine pathology
* CT verified ankylosis
* BMI\>30

Primary outcomes:
measure: Oswestry Disability Index (ODI)
timeFrame: 12 months
measure: Visual Analogue Scale (VAS) 0 to 10
timeFrame: 12 months
Secondary outcomes:
measure: Healing Measured by CT
timeFrame: 12 months
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Oslo university hospital - Ulllevaal
Study officials:
affiliation: Oslo university hosptal - Ullevaal
name: Thomas J Kibsgaard, PhD student
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02316301: Optimal Timing of Misoprostol Administration Prior to Office Hysteroscopy
Official title: Optimal Timing of Misoprostol Administration Prior to Office Hysteroscopy; a Randomized Controlled Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Pain
Keywords: Misoprostol, pain, office hysteroscopy
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2014-12-12
Enrollment: 120
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study was to determine whether misoprostol administered 12 hours before office hysteroscopy can relieve pain more effectively compared with misoprostol administered 3 hours before office hysteroscopy.

Detailed description: The interval between misoprostol administration and office hysteroscopy may have an influence on its effectiveness in pain reduction. There are limited data on the optimal interval from administration of misoprostol and office hysteroscopy. In previous studies, time interval from administration of misoprostol and office hysteroscopy ranged between 2 hours and 24 hours.

Till now no studies have yet investigated the optimal timing of misoprostol administration prior to office hysteroscopy or operative hysteroscopy. The aim of this study was to determine whether misoprostol administered 12 hours before office hysteroscopy can relieve pain more effectively compared with misoprostol administered 3 hours before office hysteroscopy

Eligibility criteria: Inclusion Criteria:

* Nulliparous patients who have an indication for office hysteroscopy

Exclusion Criteria:

* Parous patients, menopausal patients and patients with cervical pathology, and previous cervical surgery will be excluded from the study. Moreover, patients with severe vaginal bleeding, acute pelvic inflammatory disease, glaucoma, allergy to misoprostol, cardiac, liver or kidney diseases

Primary outcomes:
measure: Intensity of pain
timeFrame: up to 30 minutes
Secondary outcomes:
measure: Duration of procedure
timeFrame: intraoperative
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Obstetrics and Gynecology Department,Cairo university
Study officials:
affiliation: Cairo University
name: Usama M Fouda, M.D,PhD
role: STUDY_DIRECTOR
References:
citation: Cicinelli E, Rossi AC, Marinaccio M, Matteo M, Saliani N, Tinelli R. Predictive factors for pain experienced at office fluid minihysteroscopy. J Minim Invasive Gynecol. 2007 Jul-Aug;14(4):485-8. doi: 10.1016/j.jmig.2007.03.008.
citation: Fouda UM, Gad Allah SH, Elshaer HS. Optimal timing of misoprostol administration in nulliparous women undergoing office hysteroscopy: a randomized double-blind placebo-controlled study. Fertil Steril. 2016 Jul;106(1):196-201. doi: 10.1016/j.fertnstert.2016.03.022. Epub 2016 Mar 31.
Clinical trial NCT06978101: Visual Field Changes and OCT Angiographic Chorioretinal Changes in Patients With Primary Open Angle Glaucoma
Official title: Correlation Between Visual Field Changes and OCT Angiographic Chorioretinal Changes in Patients With Primary Open Angle Glaucoma
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Visual Field
OCT Angiography
Chorioretinal Changes
Primary Open Angle Glaucoma
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2025-05-18
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This prospective cohort nonrandomized trial was carried out on 100 cases with primary open-angle glaucoma (POAG) group (n=80): had intraocular pressure (IOP)\>21 mmHg, and control group (n=20): without family history of POAG, IOP ˂21mm Hg.

Brief summary: This study aimed to assess the correlation between visual field changes and optical coherence tomography (OCT) angiography changes of retinal nerve fiber layer in patients with primary open angle glaucoma.

Detailed description: Glaucoma is the leading cause of irreversible blindness worldwide. Since glaucomatous damage is preventable but irreversible, an early diagnosis and close follow-up of glaucoma patients are primordial. Optical coherence tomography angiography (OCTA) is a recently developed, noninvasive imaging modality that detects blood flow through the motion contrast generated by red blood cells.

Currently, there are 2 groups of complementary exams used for the diagnosis and follow-up of glaucoma patients: structural (where OCT has a considerable role) and functional (visual field) optic nerve measurements, Both technologies have strengths and limitations.

A new technology for diagnosis and follow-up that can avoid the limitations summarized above is lacking. OCTA seems to be a good candidate for such a role, OCT can detect the Doppler frequency shift of the backscattered light that provides information on blood flow.

Eligibility criteria: Inclusion Criteria:

* Primary open angle glaucoma patients.

Exclusion Criteria:

1. Hazy media.
2. Diabetic Retinopathy.
3. Uveitis.
4. Other Glaucomas

   * Acute congestive glaucoma
   * Secondary glaucomas

Primary outcomes:
measure: Peripapillary vessel density (PpVD)
timeFrame: 12 months post-procedure
Secondary outcomes:
measure: Pattern standard deviation (PSD)
timeFrame: 12 months post-procedure
measure: Mean deviation (MD)
timeFrame: 12 months post-procedure
measure: The thickness of the peripapillary retinal nerve fiber layer(RNFL)
timeFrame: 12 months post-procedure
measure: Intraocular pressure (IOP)
timeFrame: 12 months post-procedure
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Assiut university
Study officials:
References:
Clinical trial NCT06511401: Informing Pain Treatment Using Pharmacogenomic Analysis
Official title: C-PAIN: Catalyzing Pharmacogenomic Analysis for Informing Pain Treatment
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Adult Patients Who Are Receiving Oncologic Care
Keywords: Pharmacogenomic
Opioids
Lead sponsor: University of Chicago
Sponsor class: OTHER
Collaborators: name: National Human Genome Research Institute (NHGRI)
First posted: 2024-07-22
Enrollment: 800
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This is a randomized, prospective study to evaluate the effects of preemptive pharmacogenomic (PGx) testing on opioid dosing decisions/selections and pain score in cancer patients.


Eligibility criteria: Inclusion Criteria:

* Persons receiving ongoing oncology care at the University of Chicago Medical Center for whom near-future pain opioid pain medication therapy is anticipated
* Subjects must be at least 18 years of age.

Exclusion Criteria:

* Subjects taking an opioid at the time of enrollment, or within the past 30 days
* Subjects who are currently undergoing palliative radiation
* Subjects who have undergone, or are being actively considered for, bone marrow, liver or kidney transplantation.
* Subjects with a history of or active blood cancer (e.g., leukemia).
* Chronic kidney disease, as defined by Glomerular filtration rate (GFR) \< 30/mL/min/1.73m2, due to the risk of decreased drug excretion.
* Liver dysfunction, as defined by the following laboratory values, due to the risk of decreased drug metabolism: Total bilirubin greater than or equal to1.5 mg/dL, Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) greater than or equal to 2.5 X upper limit of normal\*. (\*Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) \\ greater than or equal to 5 X upper limit of normal if hepatic metastases are present).
* Inability to understand and give informed consent to participate in the opinion of the investigator
* Subjects who are known to be pregnant at the time of enrollment
* Subjects who have previously or are currently enrolled in another institutional pharmacogenomic genotyping study, or are known to have previously undergone pharmacogenomic genotyping for the gene(s) of interest via another commercial or other means.

Primary outcomes:
measure: Pain control.
timeFrame: 45 days
Secondary outcomes:
measure: Pain Medication Regimen Changes
timeFrame: 45 days
measure: Hospitalization or Emergency Visit for Pain Control
timeFrame: 45 days
measure: Cumulative Morphine Equivalents Required
timeFrame: 45 days
measure: Type of First Opioid Prescribed
timeFrame: From enrollment until study end (up to 5 years)
Other outcomes:
Locations:
city: Chicago
country: United States
facility: University of Chicago Medicine Comprehensive Cancer Center
state: Illinois
Study officials:
affiliation: University of Chicago
name: Peter H O'Donnell
role: PRINCIPAL_INVESTIGATOR
References: